For Britons of a certain age, the phrase “Don’t mention the war” needs no introduction. It’s the most famous line from the most famous episode of the 1970s comedy series Fawlty Towers, in which an inept British hotelier manages to repeatedly insult his German guests. The line is now sometimes used here as a coded instruction to avoid any difficult or awkward subject. But it can be used literally too. So, is there a degree […]
R1 Therapeutics launches with oversubscribed $77.5 million Series A financing to advance first-in-class treatment for hyperphosphatemia in patients with chronic kidney disease R1 Therapeutics, Inc, a clinical-stage biopharmaceutical company focused on the development of first-in-class therapies for patients with kidney disease, announced its launch with an oversubscribed $77.5 million Series A financing, along with the […]
Novo Holdings announces 2025 Annual Results Novo Holdings announced its financial results for 2025. Despite a challenging global environment, Novo Holdings has made significant progress on its Strategy 2030 during 2025 and delivered on its priorities. The Novo Holdings Investment Portfolio continued to perform well on both an absolute and relative basis, with a return […]
PDUFA action date for Hansa Biopharma’s imlifidase BLA set for December 19, 2026 Hansa Biopharma announced that the Food and Drug Administration (FDA) has notified the company that the previously accepted Biologics License Application (BLA) for imlifidase has been assigned a Prescription Drug User Fee Act (PDUFA) action date of December 19, 2026. 📺Optimum TV […]
In a few weeks’ time NICE – England and Wales’s drugs cost regulator – is set to make it a little easier for drugs to be approved for NHS use on cost grounds. Specifically, the cost ceiling is going to rise. This ceiling – the so-called “QALY threshold” – is actually a range. And that range is going to go up from £20 – […]
